| INTRODUC TI ON
Cancer is one of the most deadly diseases that has been a considerable challenge in clinical treatment. The conventional chemotherapies provide limited benefits through inflicting DNA damage, with cancer cells and highly proliferative tissues particularly vulnerable to this damage. 1 However, due to formidable side-effects of chemotherapeutic drugs, such as myelosuppression and digestive tract side-effects, cancer research scientists have focused their efforts on seeking better curative options. With the deeper understanding of cancer cell molecular biology, targeted therapies, including mAbs or small molecular inhibitors directed against genes or proteins that are crucial to cancer progression, novel treatment approaches have been developed, leading to therapeutic revolution. Well-designed Abs or small molecules are able to specifically attack cancer cells through blocking signal transduction, which has been verified for cancer cell growth. 2, 3 Targeted therapies have achieved dramatic success in treating cancer patients. However, rapidly developed resistance (acquired resistance) is a common phenomenon in the use of targeted drugs. 4 Thus, finding approaches to overcome acquired resistance or avoid intrinsic resistance is becoming an unmet need to improve anticancer efficacies in targeted therapies. The combination of targeted drugs with other known agents is one efficient approach to overcome resistance and enhance efficacy.
Metformin, a widely prescribed drug for treating type II diabetes, is one of the most extensively recognized metabolic modulators, which has shown an important anticancer properties. 5 Its general molecular mechanisms in inhibiting tumor growth are briefly summarized in Figure 1 . [5] [6] [7] Activation of AMPK and inhibition of mitochondria complex I are two major mechanisms of action. 5, 6 It showed significant synergy with chemotherapeutic drugs in both in vitro and in vivo models through broad-spectrum action mechanisms, as we previously described. 8 More interestingly, both preclinical and clinical evidence has profoundly indicated the improvement of targeted therapeutic efficacies by combining metformin with targeted drugs, including our recent report. 9 In this review, we summarize recent progress of strategies for treating cancer patients by combining metformin with targeted therapies, detailing the underlying mechanisms and discussing the future clinical transformation potential.
| COMB INATI ON OF ME TFORMIN WITH S MALL MOLECUL AR INHIB ITOR S
Small molecular inhibitors are one of the major types of targeted drugs, which are usually organic compounds isolated from natural products or synthesized at an industrial scale. These small molecules exert their anticancer action through blocking signal transduction.
The main portion of targeted drugs approved by the FDA for cancer treatment is made up of kinase inhibitors, with 38 approved to date. 10 As shown in Figure 2 , the number of FDA-approved targeted inhibitors increased annually from 1995 to 2017. 18 Metformin also suppressed epithelial-mesenchymal transition and the interleukin-6/STAT3 pathway, abrogating the acquired resistance of gefitinib. 17 Overcoming EGFR-tyrosine kinase inhibitor primary resistance has also been reported in NSCLC by suppressing the IGF-1R signaling pathway. 19 Interstitial lung disease is a serious The objective response rate and disease control rate were also significantly higher (70.5% vs 45.7%, P = 0.017; 97.7% vs 80.4%, P = 0.009), indicating that metformin improved survival and delayed onset of acquired resistance to gefitinib. 21 Based on these promising clinical data, a new multicenter double-blind phase II study of metformin with gefitinib as first-line therapy for locally advanced NSCLC is underway. 22 Our group has studied the synergy between metformin with gefitinib in bladder cancer. 9 We found that the combination of Metformin either targets tumor cells directly or reverses and/or inhibits epithelial-mesenchymal transition (EMT), differentiation, self-renewal, and gene mutation/alteration of signaling pathways, which are the consequence of gefitinibinduced resistance, thus sensitizing the antitumor effect or reducing the drug resistance to gefitinib metformin and gefitinib induced a stronger antiproliferative and anticolony-forming effect compared to either metformin or gefitinib alone. 9 Apoptosis was significantly increased. Gefitinib suppressed EGFR signaling and inhibited phosphorylation of ERK and Akt, which was amplified when metformin was added. 9 Interestingly, gefitinib induced activation of the AMPK signaling pathway, which was enhanced in metformin treatment as well. In vivo intravesical treatment of metformin and gefitinib on syngeneic orthotopic bladder cancer in mice confirmed the significant inhibitory effect on bladder tumor growth. 9 These 2 drugs could be an excellent combination for the treatment of bladder cancer through intravesical instillation. 
| Combination of metformin with gefitinib
F I G U R E 2
| Combination of metformin with sorafenib
Sorafenib is a multiple target kinase inhibitor that targets the angiogenic receptor tyrosine kinases, VEGFR2 and platelet-derived growth factor receptor-β. 25 Furthermore, adding metformin enabled a 25% dose reduction of sorafenib without loss of its tumor inhibitory efficacy. 29 Metformin also enhanced the antimetastatic effects of sorafenib and reduced lung metastasis in HCC. Metformin suppressed the migration and invasion of HCC cells through downregulation of the ERK/JNKmediated nuclear factor-κB-dependent pathway, resulting in the reduction of uridylyl phosphate adenosine and MMP-9 expression. 30 Metformin also upregulated expression of Tat-interacting protein 30, a protein that plays an important role in low-dose sorafenib-induced prometastasis. 31 The combination of metformin and sorafenib suppresses proliferation and induces autophagy of HCC by targeting the mTOR pathway. 32 In HCC xenograft tumors, combining metformin with sorafenib significantly minimized postoperative recurrence and lung metastasis through suppressing the mTOR pathway and CD37
and Ki67 expression, respectively. 33, 34 Although both in vitro and vivo data have confirmed that metformin can enhance the antitumor effect of sorafenib, the results from clinical trials are not convincing. Unexpectedly, Casadei
Gardini et al 35 did observe that metformin-treated patients experienced increased rather than decreased tumor aggressiveness and resistance to sorafenib. This might have been due to the small number of patients in the study. Thus, they recruited a larger number of patients and the results showed a lower response to sorafenib in those who developed HCC whilst undergoing chronic therapy with metformin, confirming their previous work. A possible explanation for these two clinical facts is that pretreatment of metformin decreased the levels of MAPK and inactivated PI3K pathways, which are the targets of sorafenib, inducing the resistance to sorafenib. 36 These contradictory facts from clinical and experimental results might be due to the data collected from experimental studies were not imitating diabetic conditions while data collected from clinical studies were from diabetic patients.
Thus, another type of clinical trial comparing sorafenib alone and sorafenib plus metformin under non-diabetic conditions might be more helpful to explore whether there are any benefits of metformin on HCC patients using sorafenib. Another reason is that it is not easy to achieve the effective concentrations of metformin in patients' bodies through conventional administration routes. 
| Combination of metformin with everolimus
Mammalian target of rapamycin is a serine/threonine kinase that belongs to the family of PI3K-related protein kinases. 38 It acts as a key regulator of many cellular processes such as growth, protein synthesis, and cell-cycle progression. It is also involved in several pathological conditions, including cancer, and has become a target for cancer treatments. 39 Everolimus, an oral mTOR inhibitor, was approved to treat advanced pancreatic neuroendocrine tumors in 2011. 40 Although everolimus showed valuable pharmacokinetic properties, its combination with other drugs as a potentially synergistic agent was encouraged. 41 It has been reported that combining metformin with everolimus showed synergistic effects in in vitro and in vivo cancer models. 42, 43 In breast cancer cells, cotreatment with metformin and everolimus intensified the inhibition of cell proliferation and colony formation. 44 Metformin and everolimus significantly suppressed obesity-induced tumor growth (0.5-fold and 0.3-fold). 45 It was also reported that the effect of everolimus might be associated with insulin resistance, manifesting in impaired glucose tolerance or hyperglycemia, whereas metformin could restore it. 46 Amazingly, a retrospective analysis of 445 patients with advanced pancreatic neuroendocrine tumors showed that the median PFS of patients treated with everolimus plus metformin was significantly longer than PFS for patients with diabetes receiving other treatments (median PFS, 20.8 months; hazard ratio, 0.49; 95% CI, 0.34-0.69; P < .0001), indicating that metformin sensitized everolimus efficacy in patients with pancreatic neuroendocrine tumors. 47 Unfortunately, a phase Ib study of everolimus combined with metformin for patients with advanced cancer showed that patients poorly tolerated the treatment and there are pharmacokinetic interactions between everolimus and metformin that might have implications for diabetic patients who are treated with these drugs. 
| Combination of metformin with trastuzumab
Trastuzumab was first approved for the treatment of HER2-positive breast cancer in the USA in 1998. 49 A member of the EGFR family, HER2 consists of 3 components: the intracellular tyrosine kinase domain, transmembrane lipophilic segment, and extracellular binding domain. Trastuzumab binds selectively and with high affinity to the extracellular domain, preventing HER2 cleavage and leading to its inactivation. 50 Up to 30% of breast cancers overexpress HER2 and HER2
expression is positively associated with significantly worse outcomes in patient survival than HER2-negative breast cancer. 51 Over the last few decades, trastuzumab has been shown to prolong survival and improve outcomes of HER2-positive breast cancer patients. However, trastuzumab is also associated with an increased risk of cardiotoxicity 52 and prolonged exposure to trastuzumab leads to resistance.
To overcome these side-effects of trastuzumab, the combination of trastuzumab with metformin has been explored. Vazquez-Martin et al 53 showed that metformin suppressed self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells.
Metformin significantly inhibited proliferation and clonogenicity of trastuzumab-resistant HER2-overexpressing breast cancer cells. The mechanisms of action involved disrupting HER2/IGF-1R complexes that are present only in resistant sublines. 54 In xenografts established from the pleural metastasis of a patient who was clinically resistant to trastuzumab, the combination of metformin with trastuzumab decreased tumor volume sharply by more than 4-fold, 55 implying that incorporation of metformin into trastuzumab-based regimens could provide a valuable strategy for treatment of HER2-positive breast cancer patients. Metformin also acts as a cardioprotective drug to attenuate the cardiac-damaging effects of trastuzumab in the clinic and it has been confirmed that it does not interfere with the anticancer activity of trastuzumab. 56 The phase III EMILIA trial showed trastuzumab emtansine, an Ab conjugate, significantly prolonged the PFS and OS in metastatic breast cancer patients. Metformin promotes trastuzumab emtansine drug efficacy through inducing caveolin-1 expression in breast cancer. 57 As for some HER2-positive breast carcinomas patients after trastuzumab treatment, lapatinib was usually used to inhibit cancer progression. Metformin could be a clinically useful candidate of delaying or treating lapatinib resistance by inactivating mTOR and decreasing p70S6K1 activity. 
| Combination of metformin with bevacizumab
Bevacizumab is a recombinant humanized mAb that targets all isoforms of VEGF-A, preventing the binding of VEGF-A to the endothelial cell surface receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). 65 Disappointingly, the results indicated that there were no significant differences in toxicity between the two study arms.
| D ISCUSS I ON
Cancer is a disease with a growing mortality worldwide, with an increase to 19.3 million new cancer cases per year predicted in 2025. 63 Targeted therapies have achieved notable success in some cancers;
however, significant problems including resistance and high toxicity remain to be solved. To address these limits, combining targeted drugs with known drugs has drawn considerable attention. Metformin, a small molecule discovered from a natural plant, has been used as first-line therapy for type II diabetes patients. Metformin has been newly recognized as a low-toxicity "broad-spectrum" therapeutic approach that could simultaneously target various key pathways and mechanisms in cancer treatment. 66 Thus, combining targeted thera- used between clinical trials and experimental studies. 37 Another reason is that the concentration of metformin for anticancer activity is much higher than that for antidiabetic activity. Thus, novel administration routes, rather than the conventional method, to increase the concentration of this drug could be needed. The intravesical method we developed has shown much better benefits than oral administration. 69 Another new direction for developing the clinical application of metformin is to characterize the precise targets of metformin, 
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